261 related articles for article (PubMed ID: 29080985)
21. The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention.
Trivedi K; Le V; Nelson JR
Postgrad Med; 2021 Jan; 133(1):28-41. PubMed ID: 32762268
[TBL] [Abstract][Full Text] [Related]
22. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
Ballantyne CM; Bays HE; Philip S; Doyle RT; Braeckman RA; Stirtan WG; Soni PN; Juliano RA
Atherosclerosis; 2016 Oct; 253():81-87. PubMed ID: 27596132
[TBL] [Abstract][Full Text] [Related]
23. Icosapent ethyl: a review of its use in severe hypertriglyceridemia.
Kim ES; McCormack PL
Am J Cardiovasc Drugs; 2014 Dec; 14(6):471-8. PubMed ID: 25428605
[TBL] [Abstract][Full Text] [Related]
24. Eicosapentaenoic Acid Versus Docosahexaenoic Acid as Options for Vascular Risk Prevention: A Fish Story.
Singh S; Arora RR; Singh M; Khosla S
Am J Ther; 2016; 23(3):e905-10. PubMed ID: 25828517
[TBL] [Abstract][Full Text] [Related]
25. Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA).
Brinton EA; Mason RP
Lipids Health Dis; 2017 Jan; 16(1):23. PubMed ID: 28137294
[TBL] [Abstract][Full Text] [Related]
26. Omega-3 fatty acid therapy for cardiovascular disease: justified or not?
Maki KC; Dicklin MR
Curr Opin Cardiol; 2020 Jul; 35(4):417-422. PubMed ID: 32412960
[TBL] [Abstract][Full Text] [Related]
27. A Comparative Overview of Prescription Omega-3 Fatty Acid Products.
Ito MK
P T; 2015 Dec; 40(12):826-57. PubMed ID: 26681905
[TBL] [Abstract][Full Text] [Related]
28. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review.
Jacobson TA; Glickstein SB; Rowe JD; Soni PN
J Clin Lipidol; 2012; 6(1):5-18. PubMed ID: 22264569
[TBL] [Abstract][Full Text] [Related]
29. A novel, multi-ingredient supplement to manage elevated blood lipids in patients with no evidence of cardiovascular disease: a pilot study.
Hobbs T; Caso R; McMahon D; Nymark M
Altern Ther Health Med; 2014; 20(5):18-23. PubMed ID: 25141367
[TBL] [Abstract][Full Text] [Related]
30. New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease.
Preston Mason R
Curr Atheroscler Rep; 2019 Jan; 21(1):2. PubMed ID: 30637567
[TBL] [Abstract][Full Text] [Related]
31. Potential benefits of icosapent ethyl on the lipid profile: case studies.
Hilleman DE; Malesker MA
Clin Med Insights Cardiol; 2014; 8():13-5. PubMed ID: 24516343
[TBL] [Abstract][Full Text] [Related]
32. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study).
Braeckman RA; Manku MS; Bays HE; Stirtan WG; Soni PN
Prostaglandins Leukot Essent Fatty Acids; 2013 Sep; 89(4):195-201. PubMed ID: 23992935
[TBL] [Abstract][Full Text] [Related]
33. Cardiovascular Disease Risk Reduction in Mild-Moderate Hypertriglyceridemia: Integrating Prescription of Omega-3 with Standard Treatment.
Picard F; Steg PG
Curr Atheroscler Rep; 2021 Mar; 23(6):27. PubMed ID: 33788024
[TBL] [Abstract][Full Text] [Related]
34. Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues.
Sherratt SCR; Libby P; Budoff MJ; Bhatt DL; Mason RP
Curr Atheroscler Rep; 2023 Jan; 25(1):1-17. PubMed ID: 36580204
[TBL] [Abstract][Full Text] [Related]
35. Omega-3-fatty acids: Do they prevent cardiovascular disease?
Mason RP; Sherratt SCR; Eckel RH
Best Pract Res Clin Endocrinol Metab; 2023 May; 37(3):101681. PubMed ID: 35739003
[TBL] [Abstract][Full Text] [Related]
36. Treatment of Chinese Patients with Hypertriglyceridemia with a Pharmaceutical-Grade Preparation of Highly Purified Omega-3 Polyunsaturated Fatty Acid Ethyl Esters: Main Results of a Randomized, Double-Blind, Controlled Trial.
Qi L; Zhang Q; Zheng Z; Pei Z; Mao H; Jiang T; Kazei D; Kahler E; Huo Y
Vasc Health Risk Manag; 2021; 17():571-580. PubMed ID: 34552329
[TBL] [Abstract][Full Text] [Related]
37. Systemic Bioavailability and Dose Proportionality of Omega-3 Administered in Free Fatty Acid Form Compared With Ethyl Ester Form: Results of a Phase 1 Study in Healthy Volunteers.
Offman E; Davidson M; Abu-Rashid M; Chai P; Nilsson C
Eur J Drug Metab Pharmacokinet; 2017 Oct; 42(5):815-825. PubMed ID: 28116646
[TBL] [Abstract][Full Text] [Related]
38. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications.
Bays HE; Tighe AP; Sadovsky R; Davidson MH
Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):391-409. PubMed ID: 18327998
[TBL] [Abstract][Full Text] [Related]
39. Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia.
McKenney JM; Sica D
Am J Health Syst Pharm; 2007 Mar; 64(6):595-605. PubMed ID: 17353568
[TBL] [Abstract][Full Text] [Related]
40. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review.
Oscarsson J; Hurt-Camejo E
Lipids Health Dis; 2017 Aug; 16(1):149. PubMed ID: 28797250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
